Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01649778 · ClinicalTrials.gov registry record
Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced or Metastatic Renal Cell Carcinoma
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 662
- Enrollment target
NCT01649778 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 662 participants.
The verdict
NCT01649778 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 662 participants
- Enrollment target
Study Summary
This is a global, multi-centre, long-term, prospective, observational study to evaluate treatment patterns and clinical outcomes in patients with advanced or metastatic RCC treated for the first time with pazopanib. The study is designed to enroll approximately 700-1000 patients in over the course of an enrollment period of approximately 18 months.There are no protocol-mandated visits or procedures associated with the study. Each patient is expected to participate for a maximum of 30 months or until premature discontinuation (i.e., due to death, withdrawal of consent, lost to follow-up or study termination).
Interventions
- DRUG Pazopanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 662 participants |
| Start Date | 2012-07-19 |
| Est. Completion | 2017-07-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01649778
The ClinicalTrials.gov registry entry for NCT01649778 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 662 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pazopanib is the first listed.
NCT01649778 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01649778 about?
NCT01649778 is a clinical study titled "Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced or Metastatic Renal Cell Carcinoma". This is a global, multi-centre, long-term, prospective, observational study to evaluate treatment patterns and clinical outcomes in patients with advanced or metastatic RCC treated for the first time with pazopanib. The study is designed to enroll approximately 700-1000 patients in over the course o...
What is the current status of trial NCT01649778?
This trial is currently completed. The enrollment target is 662 participants. The study started on 2012-07-19. Estimated completion is 2017-07-03.
What interventions are being tested in trial NCT01649778?
The interventions under investigation include: Pazopanib (DRUG).
Who is sponsoring clinical trial NCT01649778?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.